ClinicalTrials.gg
TerminatedNCT05589506PEEKPilotRPDUpdated Aug 21, 2025

Partial Rehabilitation Using a PEEK-acrylic Resin Removable Partial Denture

An interventional study of Removable partial denture PEEK in Prosthesis Survival, sponsored by Malo Clinic. Terminated at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Malo Clinic · Not applicable, Interventional, and Treatment

Why this study was terminated
Invibio Ltd, producer of the PEEK material decided to leave the market and stop production.

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Dec 2019, registered Oct 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the outcome of a Poly-ether-ether-ketone - acrylic resin removable partial denture used in partial edentulous rehabilitation after one year of follow-up. The main question it aims to answer is:

- What is the survival outcome of partial rehabilitations using Poly-ether-ether-ketone-acrylic resin removable partial dentures? The participants will receive a definitive removable partial denture incorporating Poly-ether-ehter-ketone.

Read the detailed description

Folowing the recent applications of polyetheretherketone (PEEK) material in Dentistry it is necessary to further extend the evaluation to the use of Removable Partial Denture (RPD) rehabilitations. To test this, the study design to be used will be a single-centre, prospective observational cohort study to evaluate the short term outcome of the Removal Partial Denture (RPO) supported rehabilitations. The sample of this study consists in 10 patients consecutively treated. The cohort will be evaluated at baseline, RPD design, dental fitting, follow-up assessment at 4 weeks, 6 and 12 months after dental loading regarding: JUVORA prosthetic survival including repair and relining, assessment of the adaptation of the RPD frame, adaptation of the tissue base areas and their relationship to the frame adaptation, functional evaluation, aesthetics assessment (staining, color stability, anatomic form), oral health assessment of the RPD abutment teeth periodontium (plaque index, gingival index, probing pocket depths, bleeding on probing, mobility) incidence of mechanical complications (loosening or fracture of prosthetic components), patient assessment of RPD comfort, aesthetics and chewing ability; assessment of RPD preparation (technician satisfaction) concerning laboratory preparation time, clinical operative time and costs.

02

Conditions studied

  • Prosthesis Survival

Browse trials for

Keywords

  • prosthesis
  • removable partial denture
  • PEEK
03

In context

Prosthesis Failure

119 studies on the registry are indexed under Prosthesis Failure; 35 are open to participants now.

This study's enrollment of 10 is below the median of 36 across 69 interventional studies indexed under Prosthesis Failure.

Browse Prosthesis Failure studies →

Lead sponsor

Malo Clinic is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • partial edentulism with at least a posterior natural tooth occlusaI stop (molar or premolar), defined as Kennedy's Class I, Class lI or Class lII,
  • occlusal spacing (static and dynamic) around clasp assembly including the occlusal rest;
  • previous denture wearing experience,
  • stable oral health in terms of absence of disease activity affecting the periodontium, caries, pulp and the structural/aesthetic integrity of restored teeth.
  • Subjects who, in the opinion of the Investigator, are able to understand this clinical study, co-operate with the procedures and are willing to return to the clinic for all the required post-operative follow-ups.
  • Subjects who are able to give voluntary, written to participate in this clinical study and from whom consent has been obtained.

Exclusion criteria

Exclusion Criteria:

  • Female Subjects who are pregnant;
  • Subjects requiring extensive treatment prior to the provision of a removable partial denture;
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-ups or treatment outcomes;
  • Subjects who are currently enrolled in a clinical study;
  • Subjects requiring or currently having ongoing orthodontic treatment;
  • Subjects with an opposing Removable Partial Denture (RPD).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Removable partial denture PEEK

    Removable partial denture using PEEK-acrylic resin

    Device: Removable partial denture PEEK

Interventions

  • DeviceRemovable partial denture PEEK

    A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.

    Also known as: PEEK prosthesis

06

What researchers measure

Primary outcomes

  1. Survival of the prosthesis

    Evaluation of the survival for the PEEK-acrylic resin removable partial denture; nominal (survival,failure)

    Time frame: one year

Secondary outcomes

  1. Assessment of the adaptation of the RPD frame

    Nominal: 0: adapted; 1: not adapted

    Time frame: one year

  2. Function of RPD is excellent

    5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: one year

  3. Aesthetics of RPD are excellent

    5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: one year

  4. Staining of RPD is absent

    5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: one year

  5. Color stability is maintained

    5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: one year

  6. Anatomic form of RPD is maintained

    5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree

    Time frame: one year

  7. Incidence of mechanical complications

    Loosening or fracture of prosthetic components Nominal: O: absence; 1: presence

    Time frame: one year

  8. Incidence of biological complications

    Presence of periodontal pathology Nominal: O: absence; 1: presence

    Time frame: one year

  9. Plaque accumulation around RPD abutment teeth.

    Simplified Oral Hygiene Index (Greene and Vermelion, 1964). Ordinal: 0: no debris or stain present; 1: Soft debris covering not more than one third of the tooth surface, or presence of extrinsic stains without other debris regardless of surface area covered; 2: Soft debris covering more than one third, but not more than two thirds, of the exposed tooth surface; 3: Soft debris covering more than two thirds of the exposed tooth surface.

    Time frame: one year

  10. Bleeding around RPO abutment teeth

    Gingival index (Loe and Silness 1963)'. Ordinal: 0: absence of inflammation/normal gingiva; 1: mild inflammation, slight change in color, slight edema, no bleeding on probing; 2: moderate inflammation, moderate glazing, redness, edema and hypertrophy, bleeding on probing; 3: severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding.

    Time frame: one year

  11. Probing pocket depths around RPD Dependent variable abutment teeth measured in millimeters

    Measured through probing with a periodontal probe, evaluated on all tooth aspects. Scale: Distance between mucosal margin and probe stop measured in millimeters.

    Time frame: one year

  12. Mobility of RPO abutment teeth

    Mobility classification (Miller 1950). Ordinal: 0: no detected mobility; 1: first sign of movement greater than normal; 2: up to 1 mm in any direction; 3: more than 1 mm in any direction and/or vertical depression.

    Time frame: one year

  13. ln mouth comfort

    Visual analogue scale (0-10 cm); 0:very poor; 10: very good

    Time frame: one year

  14. Oral Health Impact Profile OHIP-14

    Oral Health Impact Profile OHIP-14 questionnaire

    Time frame: one year

07

Study locations

1 site
  • Malo Clinic
    Lisbon, Lisbon District 1600-042, Portugal
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized database containing the study variables

Supporting information: Statistical analysis plan

Time frame: Upon study completion and for 8 years.

Access criteria: Upon solicitation to the Investigators

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2025, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 21, 2022
StartActual
Dec 13, 2019
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05589506
Lead sponsor
Malo Clinic
Collaborators
Invibio Ltd
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Dec 13, 2019
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
Aug 21, 2025

Study contacts

Miguel A de Araújo Nobre, PhD
principal investigator · Director of Research, Development and Education

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion